Control of the Hyperlipidemias To the Editor: I write on behalf of the 838 patients in the Program on the Surgical Control of the Hyperlipidemias (POSCH) trial; its principal investigators; and the members of the POSCH Data Monitoring Committee, including the late Drs Thomas C. Chalmers and Samuel W. Greenhouse, and Drs J. Ward Kennedy, Gerald R. Cooper, Paul Meier, Curtis L. Meinert, Jeremiah ...

A member of the Liliaceae family, garlic (Allium sativum) is highly regarded throughout the world for both its medicinal and culinary value. Early men of medicine such as Hippocrates, Pliny and Aristotle encouraged a number of therapeutic uses for this botanical. Today, it is commonly used in many cultures as a seasoning or spice. Garlic also stands as the second most utilized supplement. With ...

Mendelian disease (due to disruption of a single gene) will be dealt with first as it accounts for a considerable proportion of endocrine disorders, represents the simplest and best understood instance of the contribution of genetics to endocrinology, and has given rise to routine diagnostics already available to clinicians. Complex disorders, depending on the interaction of environmental facto...

T he scientific community has by now generally accepted that human atherosclerosis development can be influenced by therapeutic means. This insight has mainly been based on studies of the coronary arteries, the conclusive one being the Cholesterol Lowering Atherosclerosis Study (CLAS)1 but supported by studies like the National Heart, Lung, and Blood Institute (NHLBI) study,2 the Helsinki Coron...

Partial ileal bypass (PIB) is a safe, effective, and lasting therapy for the reduction of lipids and lipoproteins in patients with hyperlipidemia. Following PIB, cireulating plasma and low-density lipoprotein (LDL) cholesterol fall markedly, while high-density lipoprotein (HDL) cholesterol rises. The average plasma cholesterol lowering is 25 % after diet, with a 40 % reduction in the LDL-choles...

In short-term trials chlorophenoxyisobutyric acid (CPIB) (Atromid-S) reduced the plasma cholesterol and triglyceride levels in eight subjects with type II and IV hyperlipidemias to an equal extent. In these subjects, who were maintained on constant solid food diets, CPIB administration resulted in increased excretion of fecal neutral and acidic sterols in the type II subjects only. There was an...